Blue Earth Therapeutics Ltd, an Oxford, UK-based chief within the growth of therapeutic radiopharmaceuticals, closed a $76.5M Collection A financing.
The spherical was led by Soleus Capital and co-led by Sands Capital Administration with present investor Bracco Imaging SpA additionally taking part. Woodline Companions and PBM Capital additionally joined within the financing as new institutional buyers.
The brand new funding permits the corporate to additional advance its medical stage PSMA-targeted radioligand therapies.
Led by David Gauden, CEO, Blue Earth Therapeutics is a medical stage firm devoted to advancing subsequent era focused radiotherapeutics to deal with sufferers who’ve most cancers and has been incubated inside the Bracco household of corporations. With confirmed administration experience throughout the spectrum of radiopharmaceutical and oncology drug growth, in addition to biotechnology begin‐up expertise, the corporate goals to innovate and enhance upon present applied sciences and quickly advance new focused therapies for severe illnesses. Blue Earth Therapeutics has an rising pipeline initially centered on prostate most cancers. For extra data, please go to: .
David Canner from Soleus Capital and Michael Ginder from Sands Capital Administration are becoming a member of the Board of Administrators alongside representatives from Bracco Imaging SpA and skilled trade CEO David Gauden.
FinSMEs
31/10/2024
